17th January 2023

Bridge Therapeutics Predicts Better Management of Opioid Use Disorder through the MAT Act

Bridge Therapeutics, today said that the MAT Act removes the outdated registration requirements on buprenorphine, making it possible for providers nationwide to prescribe it as they would any other controlled medication. Buprenorphine is a partial agonist or partial-acting opioid that treats addiction and chronic pain more safely than full-agonist opioids like morphine, oxycodone and fentanyl.

For more information about Bridge Therapeutics please contact us today using the form below.